ABNewswire - Press Release Distribution Service

Tuesday, February 28, 2023

Bollywood's Biggest Stars to Make Debut in Atlanta with The Entertainers Tour

Dharma Productions, Akshay Kumar, Garg Group, Anip Patel, and Anand Entertainment host a night of dinner, dance and drinks to celebrate the launch of the Entertainers Tour.

February 28, 2023 - Atlanta, GA - The Entertainers Tour is making its debut in Atlanta, bringing some of Bollywood's biggest stars to the United States for a night of entertainment and celebration. The tour will kick off on March 3, with a star-studded launch party hosted by the Garg Group, Anand Entertainment & Anip Patel on March 1st.

The launch party is an intimate affair, with some of the biggest celebrities and influencers in America joining the Bollywood stars for a night of fun and entertainment. The event will feature a red carpet, allowing fans to glimpse their favorite stars as they make their way into the party.

“I can’t wait to co-host this event alongside the national promoters Garg Group and Anand Entertainment. The team and I are thrilled to bring in some of the best in the business from Bollywood and showcase our rich culture of song and dance," says Anip Patel, CEO of CaPatel Investments.

The Entertainers Tour promises to be a night of non-stop entertainment, with an incredible lineup of performances from some of the most talented artists in Bollywood. Fans can expect to see dance numbers, dramatic scenes, and more, all brought to life by these renowned performers.

Tickets for The Entertainers Tour are on sale now and are available to purchase by location here. Take your chance to be a part of this unforgettable event and experience the excitement of Bollywood in Atlanta.

About The Entertainers Tour

The Entertainers Tour will go coast to coast across North America. It will be filled with energetic performances by critical figures in Bollywood such as Akshay Kumar, Disha Patani, Mouni Roy, Nora Fatehi, and Sonam Bajwa, to name a few. For more information about The Entertainers Tour visit Instagram @theentertainerstour.

About Anip Patel

Anip Patel founded CaPatel Investments in 2022 with the ultimate goal to invest in start-ups founded by South Asians to help them succeed. At CaPatel Investments, he relentlessly seeks out South Asian companies that can deliver returns to investors while providing value to South Asian entrepreneurs. Anip is both an entrepreneur and an investor. He has founded many companies in tech, healthcare, and entertainment. He invests across sectors and stages, with a passion for companies reinventing huge industries. Prior to starting CaPatel Investments, Anip graduated from DePaul with a triple major in finance, marketing, and economics. He soon started doing management consulting for some of the Fortune 500 companies then pivoted to starting his own startups.

Media Contact
Company Name: Otter PR
Contact Person: Chandni Desai
Email:Send Email
Phone: 8136786828
Address:320 1st Ave N Suite 110
City: St. Petersburg
State: Florida
Country: United States
Website: OtterPR.com

2022 was an Epic Fishing Season in the Pacific Northwest but 2023 is Looking Even Better

2022 was an epic year for Reel Time Fishing we experienced the best run of Steelhead since the early 2000's great numbers of Idaho's crown jewel the extra-large B run steelhead were plentiful.

The Clearwater River has always been known for large fish but this year mass amounts of Steelhead over 20 lbs. were caught. Dworshak national fish hatchery in Orofino Idaho is the largest Steelhead hatchery in the world.

Perhaps the most exciting event was Reel Time Pro guide Travis Wendt breaking the Idaho state catch and release record catching a 9lb smallmouth, only to be topped by fellow Reel Time pro guide Joey Walton 9.14 lb.

Experts believe the next world record Smallmouth Bass may come out of Dworshak reservoir this high mountain lake boasts a massive population of very small Kokanee combine that with somewhat mild winter water temperature allowing these bass to feed and grow year round.

2023 is poised to be another excellent year first up is another banner run of spring chinook it has been 5 years since we had a fishable spring King Salmon run in the Clearwater river 2022. They returned in wonderful numbers and we were able to have a spectacular season. These highly prized fish are the most sought after Salmon in the pacific northwest fetching upwards of $50 lb at Pike Place Market.

We will begin fishing these fish late march in Portland Oregon and follow them up the Columbia stopping at Wind River, Drano Lake, Hood River, Dalles, Rufus and Umatilla Oregon into the Snake River fishing below Ice Harbor and Little Goose dams and finally the Clearwater river. Reel Time Fishing guides are the only guides to follow these fish along there migration keeping you fishing for the largest pulse of these migrating fish. Be sure to follow our fishing reports on our website for the latest updates and news.

Media Contact
Company Name: Reel Time Fishing
Contact Person: Toby Wyatt
Email:Send Email
Phone: 208-790-2128
Address:2131 Critchfield Road
City: Clarkston
State: WA 99403
Country: United States
Website: www.reeltimefishing.com

Triple Negative Breast Cancer Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - AstraZeneca plc., Pfizer, Inc., F. Hoffman La Roche

The Triple Negative Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Triple Negative Breast Cancer pipeline products will significantly revolutionize the Triple Negative Breast Cancer market dynamics.

DelveInsight’s “Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Triple Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Triple Negative Breast Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Triple Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Triple Negative Breast Cancer Market Insights

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there isa lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

Some of the key facts of the Triple Negative Breast Cancer Market Report:

The Triple Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Amongst all the 7MM countries, the EU-5 countries (combined) accounted for the highest number of incident cases, followed by the United States
During the ESMO 2021, Novartis presented data from the Phase II study of LAG525 in combination with natalizumab (PDR001), PDR001 and carboplatin, as first- or second-line therapy inadvanced TNBC patients
Total Diagnosed Incident cases of Triple Negative Breast Cancer in the 7MM countries was 99,380 in 2017
The Sub-type specific cases of TNBC, which are ER-, PR- and HER2- . In the United States, there were 4,793 cases of HER2-TNBC, followed by PR- and ER- subtypes.
Key Triple Negative Breast Cancer Companies: AstraZeneca plc., Pfizer, Inc., F. Hoffman - La Roche Ltd., Channel Strategy, Novartis AG, Mylan N.V., Eli Lilly and Company, Celgene Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., HiberCell, Infinity Pharmaceuticals, CytoDyn, NeoImmuneTech, Medicenna, and others
Key Triple Negative Breast Cancer Therapies: Imprime PGG, Tecentriq, IPI-549 (Eganelisib), Leronlimab (PRO 140), CFI-400945, MDNA11, and others
The Triple Negative Breast Cancer epidemiology based on gender analyzed that Triple Negative Breast Cancer affects females more than males

Get a Free sample for the Triple Negative Breast Cancer Market Report -

https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Key benefits of the Triple Negative Breast Cancer Market report:

Triple Negative Breast Cancer market report covers a descriptive overview and comprehensive insight of the Triple Negative Breast Cancer Epidemiology and Triple Negative Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Triple Negative Breast Cancer market report provides insights on the current and emerging therapies.
Triple Negative Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Triple Negative Breast Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Triple Negative Breast Cancer market.

Download the report to understand which factors are driving Triple Negative Breast Cancer epidemiology trends @ Triple Negative Breast Cancer Epidemiological Insights

Triple Negative Breast Cancer Market

The dynamics of the Triple Negative Breast Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Triple Negative Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Triple Negative Breast Cancer Epidemiology Segmentation:

The Triple Negative Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Triple Negative Breast Cancer
Prevalent Cases of Triple Negative Breast Cancer by severity
Gender-specific Prevalence of Triple Negative Breast Cancer
Diagnosed Cases of Episodic and Chronic Triple Negative Breast Cancer

Triple Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Triple Negative Breast Cancer market or expected to get launched during the study period. The analysis covers Triple Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Triple Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Triple Negative Breast Cancer market share @ Triple Negative Breast Cancer market forecast

Triple Negative Breast Cancer Therapies and Key Companies

Imprime PGG: HiberCell
Tecentriq: Hoffmann-La Roche
IPI-549 (Eganelisib): Infinity Pharmaceuticals
Leronlimab (PRO 140): CytoDyn
CFI-400945: NeoImmuneTech
MDNA11: Medicenna

Triple Negative Breast Cancer Market Drivers

Advancements in Genomics and Proteomics
Emergence of Immunotherapies
Improved Treatment Deliverance
Increase in Number of Research Articles

Scope of the Triple Negative Breast Cancer Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Triple Negative Breast Cancer Companies: AstraZeneca plc., Pfizer, Inc., F. Hoffman - La Roche Ltd., Channel Strategy, Novartis AG, Mylan N.V., Eli Lilly and Company, Celgene Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., HiberCell, Infinity Pharmaceuticals, CytoDyn, NeoImmuneTech, Medicenna, and others
Key Triple Negative Breast Cancer Therapies: Imprime PGG, Tecentriq, IPI-549 (Eganelisib), Leronlimab (PRO 140), CFI-400945, MDNA11, and others
Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Triple Negative Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Triple Negative Breast Cancer Market Access and Reimbursement

Triple Negative Breast Cancer Market Barriers

Use of Off Label Therapies and Generics
High Treatment Cost
Fewer Patients Available for Clinical Trials
High Recurrence Rate
Multiple Treatment Challenges

Table of Contents

1. Triple Negative Breast Cancer Market Report Introduction

2. Executive Summary for Triple Negative Breast Cancer

3. SWOT analysis of Triple Negative Breast Cancer

4. Triple Negative Breast Cancer Patient Share (%) Overview at a Glance

5. Triple Negative Breast Cancer Market Overview at a Glance

6. Triple Negative Breast Cancer Disease Background and Overview

7. Triple Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Triple Negative Breast Cancer

9. Triple Negative Breast Cancer Current Treatment and Medical Practices

10. Triple Negative Breast Cancer Unmet Needs

11. Triple Negative Breast Cancer Emerging Therapies

12. Triple Negative Breast Cancer Market Outlook

13. Country-Wise Triple Negative Breast Cancer Market Analysis (2019–2032)

14. Triple Negative Breast Cancer Market Access and Reimbursement of Therapies

15. Triple Negative Breast Cancer Market Drivers

16. Triple Negative Breast Cancer Market Barriers

17. Triple Negative Breast Cancer Appendix

18. Triple Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Triple Negative Breast Cancer treatment, visit @ Triple Negative Breast Cancer Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

ESR1-Mutated Metastatic Breast Cancer Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Roche, Sermonix Pharmaceutical, Sanofi

The ESR1-Mutated Metastatic Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage ESR1-Mutated Metastatic Breast Cancer pipeline products will significantly revolutionize the ESR1-Mutated Metastatic Breast Cancer market dynamics.

DelveInsight’s “ESR1-Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the ESR1-Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1-Mutated Metastatic Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The ESR1-Mutated Metastatic Breast Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the ESR1-Mutated Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ESR1-Mutated Metastatic Breast Cancer Market Insights

ESR1-Mutated Metastatic Breast Cancer Overview

Breast cancer occurs when cells in the breast grow out of control and form a growth or tumor.

Tumors may be cancerous (malignant) or not cancerous (benign). A small percentage of all breast cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Mutations in the estrogen receptor gene (ESR1) are acquired frequently in metastatic hormone receptor–positive breast cancer.

Some of the key facts of the ESR1-Mutated Metastatic Breast Cancer Market Report:

The ESR1-Mutated Metastatic Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Mutations affecting the ESR1 gene have been detected mainly in metastases from ER-positive/HER2-negative breast tumors, at a frequency ranging from 5 to 25%, when considering series with >20 interrogated metastases
ER is expressed in over 60% of breast cancers and consists of two activation function domains, AF1/2, a DNA binding domain and a hinge domain, and a ligand-binding domain (LBD).
According to the World Health Organization, breast cancer results in more than one million new cases worldwide. About 70% of diagnosed cases express estrogen receptor alpha (ER), where ER signaling is the defining and driving event contributing to tumor growth and disease progression in these ER+ breast tumors
According to SEER, 63% of the breast cancer are localized (confined to primary site), 29% of the breast cancer cases are regional (spread to regional lymph nodes), 6% of the breast cancer cases are distant (cancer has metastasized) and 2% of the breast cancer cases are unstaged
Key ESR1-Mutated Metastatic Breast Cancer Companies: Roche, Sermonix Pharmaceutical, Sanofi, and others
Key ESR1-Mutated Metastatic Breast Cancer Therapies: Giredestrant, Lasofoxifene, SAR439859, and others

Get a Free sample for the ESR1-Mutated Metastatic Breast Cancer Market Report -

https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market

Key benefits of the ESR1-Mutated Metastatic Breast Cancer Market report:

ESR1-Mutated Metastatic Breast Cancer market report covers a descriptive overview and comprehensive insight of the ESR1-Mutated Metastatic Breast Cancer Epidemiology and ESR1-Mutated Metastatic Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The ESR1-Mutated Metastatic Breast Cancer market report provides insights on the current and emerging therapies.
ESR1-Mutated Metastatic Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The ESR1-Mutated Metastatic Breast Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the ESR1-Mutated Metastatic Breast Cancer market.

Download the report to understand which factors are driving ESR1-Mutated Metastatic Breast Cancer epidemiology trends @ ESR1-Mutated Metastatic Breast Cancer Epidemiological Insights

ESR1-Mutated Metastatic Breast Cancer Market

The dynamics of the ESR1-Mutated Metastatic Breast Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

ESR1-Mutated Metastatic Breast Cancer Epidemiology

ESR1-Mutated Metastatic Breast Cancer Epidemiology Segmentation:

The ESR1-Mutated Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of ESR1-Mutated Metastatic Breast Cancer
Prevalent Cases of ESR1-Mutated Metastatic Breast Cancer by severity
Gender-specific Prevalence of ESR1-Mutated Metastatic Breast Cancer
Diagnosed Cases of Episodic and Chronic ESR1-Mutated Metastatic Breast Cancer

ESR1-Mutated Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ESR1-Mutated Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers ESR1-Mutated Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the ESR1-Mutated Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major ESR1-Mutated Metastatic Breast Cancer market share @ ESR1-Mutated Metastatic Breast Cancer market forecast

ESR1-Mutated Metastatic Breast Cancer Therapies and Key Companies

Giredestrant: Roche
Lasofoxifene: Sermonix Pharmaceutical
SAR439859: Sanofi

ESR1-Mutated Metastatic Breast Cancer Market Drivers

Increased incidence of ESR1-mutations in breast cancer in the 7MM
Increasing demand of novel drugs for ESR1 mutation treatment

Scope of the ESR1-Mutated Metastatic Breast Cancer Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key ESR1-Mutated Metastatic Breast Cancer Companies: Roche, Sermonix Pharmaceutical, Sanofi, and others
Key ESR1-Mutated Metastatic Breast Cancer Therapies: Giredestrant, Lasofoxifene, SAR439859, and others
ESR1-Mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1-Mutated Metastatic Breast Cancer current marketed and ESR1-Mutated Metastatic Breast Cancer emerging therapies
ESR1-Mutated Metastatic Breast Cancer Market Dynamics: ESR1-Mutated Metastatic Breast Cancer market drivers and ESR1-Mutated Metastatic Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
ESR1-Mutated Metastatic Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, ESR1-Mutated Metastatic Breast Cancer Market Access and Reimbursement

ESR1-Mutated Metastatic Breast Cancer Market Barriers

Challenges in the identification of ESR1 mutations in standard clinical practice
There is a paucity of ER-positive PDX models from MBC patients, especially patients with ESR1 mutations.

Table of Contents

1. ESR1-Mutated Metastatic Breast Cancer Market Report Introduction

2. Executive Summary for ESR1-Mutated Metastatic Breast Cancer

3. SWOT analysis of ESR1-Mutated Metastatic Breast Cancer

4. ESR1-Mutated Metastatic Breast Cancer Patient Share (%) Overview at a Glance

5. ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance

6. ESR1-Mutated Metastatic Breast Cancer Disease Background and Overview

7. ESR1-Mutated Metastatic Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of ESR1-Mutated Metastatic Breast Cancer

9. ESR1-Mutated Metastatic Breast Cancer Current Treatment and Medical Practices

10. ESR1-Mutated Metastatic Breast Cancer Unmet Needs

11. ESR1-Mutated Metastatic Breast Cancer Emerging Therapies

12. ESR1-Mutated Metastatic Breast Cancer Market Outlook

13. Country-Wise ESR1-Mutated Metastatic Breast Cancer Market Analysis (2019–2032)

14. ESR1-Mutated Metastatic Breast Cancer Market Access and Reimbursement of Therapies

15. ESR1-Mutated Metastatic Breast Cancer Market Drivers

16. ESR1-Mutated Metastatic Breast Cancer Market Barriers

17. ESR1-Mutated Metastatic Breast Cancer Appendix

18. ESR1-Mutated Metastatic Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about ESR1-Mutated Metastatic Breast Cancer treatment, visit @ ESR1-Mutated Metastatic Breast Cancer Medications

NFTpay's Simplified Solution Brings NFTs to the Masses with CEO Mike Krilivsky at the Helm.

Breaking down the barriers to NFT adoption with NFTpay's free and easy solution.

With NFTpay, any company selling NFTs can now offer their NFTs to a broader audience without being limited by the complex and confusing process of crypto wallets, KYC, and crypto transfers. With NFTpay, customers can buy NFTs with just a credit card in less than a minute, making it accessible for everyone, including those without prior knowledge of crypto.

Under the leadership of CEO Mike Krilivsky, NFTpay is determined to simplify the NFT and Web3 world, bringing it to billions of people in an easy and unified way. Mike Krilivsky says, “Our mission is to make NFTs accessible to everyone. NFTpay offers a payment solution that enables anyone, even those unfamiliar with crypto, to buy an NFT in just a minute. We handle all the complicated aspects, such as crypto wallets, buying cryptocurrency, KYC, and potential chargebacks, so the consumer and company can enjoy a seamless experience. The consumer's buying process is easier & companies' selling process and customer support is better because things are simple.”

As part of this mission, NFTpay has been constantly adding new features and experiences to continue to drive adoption with consumers and businesses alike. They recently rolled out features such as the NFTpay wallet API, USDC and USDT support, and NFT gaming services with other features such as ACH, Apple Pay and wire transfers coming soon.

NFTs have reached extreme heights over the last few years, and adoption will only increase going forward. With solutions like NFTpay, adoption is only expected to increase. NFTs are complex and require a series of steps, such as ensuring enough crypto in your wallet, transferring it to an external wallet, and connecting to a mint site, just to mention a few. NFTpay eliminates all these obstacles, allowing users to bypass the complexity and buy NFTs with ease. NFT founders and partners can now integrate the NFTpay credit card solution directly into their websites with 2 lines of script, making it simple and secure for customers to purchase NFTs in just a minute without any wallet requirements. Mike Krilivsky continued, “Our focus has been on making the integration process for NFT project creators and NFT marketplaces as simple as possible so that they can get started accepting credit cards with the least possible integration work. Most projects are live within 24 hours.” NFTpay leads the industry in supporting the most blockchains including Ethereum, Polygon, Solana, Avalanche, Algorand, USDC, USDT, Fantom, Telos, Binance Smart Chain, Cronos with more coming soon such as Cardano and Tezos.

NFTpay founder Mike Krilivsky believes in innovating the simple. With this in mind they have been pushing the boundaries of NFTpay and are adding new features that will drive adoption with consumers and businesses alike. They have rolled out features like NFTpay wallet API, USDC, and USDT support, and NFT gaming services with other features such as ACH, Apple Pay, and wire transfers coming soon.

With Mike Krilivsky and his team at NFTpay, NFT purchasing has never been easier and more accessible. Get ready to join the revolution in the crypto and NFT world.

Media Contact
Company Name: NFTpay
Email:Send Email
Country: United States
Website: https://nftpay.xyz/

Gritti Launches Metaverse Marathon, the First-Ever NFT Medal

C:UsersUSERDesktop2791677220712_.pic.jpg

Gritti, the revolutionary social fitness company, has launched its Global Running Infinity Tour (GRIT), a series of online and offline running events around the world. Headlining the tour is the world’s first ‘Metathon’, which will allow runners from all walks of life to enjoy metaverse-based running events curated by Gritti in parallel with prominent live marathon events such as the Abbott World Marathon Majors (Boston, Berlin, Chicago, London, New York, Tokyo).

With an estimated market value of over US$500 billion, the marathon and sports industry is a major building block of the global economy. Gritti’s Metathon is set to democratize participation in marathons, which have historically had a very high barrier to entry. Notably, the ticket cost of entering into one of the “Six Major” Marathons can be well over US$3,000 per runner, and the need for qualifying times leaves many amateur runners unable to participate.

With Metathon, Gritti will significantly lower entry barrier for all runners and create many inclusive and community-driven marathon events globally. Runners who may have previously been unable to participate in marathons due to physical, financial, or logistical limitations can now join the community, perform their best, and celebrate their accomplishments with others.

Metathon contestants will be given the opportunity to earn the inaugural NFT Medal (Soulbound) as well as a physical medal as a representation of their amazing accomplishments. This convergence of digital and physical worlds exemplifies Gritti's mission to connect web2 and web3.

The NFT medal is a soulbound NFT with a Gritt twist.

It is transferrable: instead of owners not being able to transfer the NFT medals, we link each NFT medal to the original mint wallet so as long as you prove ownership of the original mint wallet, all in-app utilities associated with the NFT medal (to be announced soon) will still be valid even if the NFT medal is no longer held by the user. Why should anyone restrict your ability to show off your medal in the digital realm?

It is irrevocable: instead of issuers having the ability to revoke ownership or certain privileges associated with soulbound NFTs, Gritti’s NFT medals are not revokable. It will record important running stats such as event categories, completion time, segmented pace stats, and rankings; so all your achievements will be recorded on-chain.

C:UsersUSERDesktopmetathon.jpg

Why is this important?

Ensuring the authenticity, traceability, and tamper resistance of sports data are of paramount importance in the marathon industry. Currently, marathon organizers rely on the data certification of the athletics association and the timing chip service provider for offline events. However, Gritti believes that the future of the industry lies in the integration of blockchain technology. Using Metathon Tokyo as a test case, with many more events to follow, Gritti is set to transform the marathon and sports industry and cement its position as a leader in sports technology innovation.

Medal Designs

One of the most unique aspects of the event is the design of the NFT medal that combines two of Tokyo’s most famous mascots, the Maneki-Neko and the Daruma doll.

The Maneki-Neko is a common cat-shaped lucky charm that symbolizes wealth and fortune in Japanese culture, while the Daruma doll is a traditional Japanese doll that is believed to bring good luck and wish fulfillment. The medal’s design also features a circuit board, which represents web3 roots but is also a nod to Japan’s technological advancements and its reputation as a leader in innovation.

The design process for the medal was a collaboration between Gritti and MUA Dao, a leading creative collective. This collaboration ensured community involvement in while also traiditional Japanese culture and values. We are focused on making Grittizens global but also local.

“At Gritti, we believe in the importance of bringing people together for a shared goal, the Metathon is no exception as we’re thrilled to offer participants a first-of-its-kind NFT medal that combines two of Tokyo’s most famous mascots,” said a spokesperson for Gritti.

The Gritti Metathon is set to take place between March 5-18, and early bird registration is now open. Running enthusiasts from around the world are invited to join the race and become part of the running revolution.

For more information about the Gritti Metathon, visit:

WEBSITE || TWITTER || DISCORD || MEDIUM

Media Contact
Company Name: Gritti
Contact Person: Emma Zhang
Email:Send Email
Country: Singapore
Website: https://www.gritti.io/

Nocturia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Allergan Inc., Urigen Pharma, Ferring Pharma, Glenmark

The Nocturia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nocturia pipeline products will significantly revolutionize the Nocturia market dynamics.

DelveInsight’s “Nocturia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nocturia, historical and forecasted epidemiology as well as the Nocturia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Nocturia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Nocturia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nocturia Market Insights

Nocturia Overview

The need for a patient to get up at night on a regular basis to urinate is called Nocturia. To be considered as a nocturnal void, a period of sleep must precede and follow the urinary episode. This means that when identifying nocturia episodes, the first morning void is ignored.

Some of the key facts of the Nocturia Market Report:

The Nocturia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
The prevalence of nocturia rises with age. There is a trend for young women to have a higher prevalence than young men, which is changed later in life. By age 80, majority of people will rise at least once per night to void (Bliwise et al., 2019)
A retrospective modelling study was conducted by Weidlich et al., to estimate the prevalence-based cost of illness imposed by nocturia (≥2 nocturnal voids per night) in Germany, Sweden, and the UK in an average year
Key Nocturia Companies: Allergan Inc., Urigen Pharmaceuticals, Ferring Pharmaceuticals, Glenmark Pharmaceuticals, Teva Pharmaceuticals Inc., AA Pharma, Avadel Pharmaceuticals, Wellesley Pharmaceuticals, Sanwa Kagaku Kenkyusho Co., Ltd./ Kyorin Pharmaceutical, Vantia Therapeutics, and others
Key Nocturia Therapies: Nocturol, SK-1404, Fedovapagon (VA106483), and others
The Nocturia epidemiology based on gender analyzed that Nocturia affects both men and women depending upon their age and causes

Get a Free sample for the Nocturia Market Report -

https://www.delveinsight.com/sample-request/nocturia-market

Key benefits of the Nocturia Market report:

Nocturia market report covers a descriptive overview and comprehensive insight of the Nocturia Epidemiology and Nocturia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Nocturia market report provides insights on the current and emerging therapies.
Nocturia market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Nocturia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Nocturia market.

Download the report to understand which factors are driving Nocturia epidemiology trends @ Nocturia Epidemiological Insights

Nocturia Market

The dynamics of the Nocturia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Nocturia Epidemiology

Nocturia Epidemiology Segmentation:

The Nocturia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Nocturia
Prevalent Cases of Nocturia by severity
Gender-specific Prevalence of Nocturia
Diagnosed Cases of Episodic and Chronic Nocturia

Nocturia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nocturia market or expected to get launched during the study period. The analysis covers Nocturia market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Nocturia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Nocturia market share @ Nocturia market forecast

Nocturia Therapies and Key Companies

Nocturol: Wellesley Pharmaceuticals
SK-1404: Sanwa Kagaku Kenkyusho Co., Ltd./ Kyorin Pharmaceutical
Fedovapagon (VA106483): Vantia Therapeutics

Nocturia Market Drivers

Expected rise in cases of Nocturia with age and also the other conditions like diabetes and kidney diseases
Emerging assets targeting underlying cause of Nocturia

Scope of the Nocturia Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Nocturia Companies: Allergan Inc., Urigen Pharmaceuticals, Ferring Pharmaceuticals, Glenmark Pharmaceuticals, Teva Pharmaceuticals Inc., AA Pharma, Avadel Pharmaceuticals, Wellesley Pharmaceuticals, Sanwa Kagaku Kenkyusho Co., Ltd./ Kyorin Pharmaceutical, Vantia Therapeutics, and others
Key Nocturia Therapies: Nocturol, SK-1404, Fedovapagon (VA106483), and others
Nocturia Therapeutic Assessment: Nocturia current marketed and Nocturia emerging therapies
Nocturia Market Dynamics: Nocturia market drivers and Nocturia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Nocturia Unmet Needs, KOL’s views, Analyst’s views, Nocturia Market Access and Reimbursement

Nocturia Market Barriers

Limited patients are approaching the physicians for treatment
Effectiveness and Safety concerns of current therapies

Table of Contents

1. Nocturia Market Report Introduction

2. Executive Summary for Nocturia

3. SWOT analysis of Nocturia

4. Nocturia Patient Share (%) Overview at a Glance

5. Nocturia Market Overview at a Glance

6. Nocturia Disease Background and Overview

7. Nocturia Epidemiology and Patient Population

8. Country-Specific Patient Population of Nocturia

9. Nocturia Current Treatment and Medical Practices

10. Nocturia Unmet Needs

11. Nocturia Emerging Therapies

12. Nocturia Market Outlook

13. Country-Wise Nocturia Market Analysis (2019–2032)

14. Nocturia Market Access and Reimbursement of Therapies

15. Nocturia Market Drivers

16. Nocturia Market Barriers

17. Nocturia Appendix

18. Nocturia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Nocturia treatment, visit @ Nocturia Medications

Polycythemia Vera Market Research Report 2032: Epidemiology Data, Therapies, Treatment, Companies and Competitive Analysis by DelveInsight

Polycythemia Vera Market

Polycythemia Vera is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis) and affected people may also have excess white blood cells and platelets. Most cases of PV are not inherited and are acquired during a person’s lifetime.

DelveInsight's “Polycythemia Vera Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Polycythemia Vera , historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Some facts of Polycythemia Vera Market report are:

In 2022, the Polycythemia Vera market size was highest in the US among the 7MM accounting for approximately USD 1,500 million that is further expected to increase by 2032.
Other emerging therapies such as Italfarmaco’s Givinostat, Silence Therapeutics’ SLN124, Ionis Pharmaceutical’s Sapablursen, and Perseus Proteomics’ PPMX-T003 have the potential to create a significant positive shift in the Polycythemia Vera market size.
The total prevalent cases of Polycythemia Vera in the 7MM comprised of approximately 309,000 cases in 2022 and are projected to increase during the forecasted period
Key polycythemia vera companies working in the market are Protagonist Therapeutics, Imago BioSciences, Italfarmaco, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics and others.

Request a sample and discover more about the report offerings at: Polycythemia Vera Market Insight

Polycythemia Vera Market

The Polycythemia Vera market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Polycythemia Vera market trends by analyzing the impact of current Polycythemia Vera therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Polycythemia Vera market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Polycythemia Vera market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Polycythemia Vera market in 7MM is expected to witness a major change in the study period 2019-2032.

Polycythemia Vera Epidemiology

The Polycythemia Vera epidemiology section provides insights into the historical and current Polycythemia Vera patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Polycythemia Vera market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Polycythemia Vera Epidemiology at: https://www.delveinsight.com/sample-request/polycythemia-vera-market

Polycythemia Vera Drugs Uptake

This section focuses on the uptake rate of the potential Polycythemia Vera drugs recently launched in the Polycythemia Vera market or expected to be launched in 2019-2032. The analysis covers the Polycythemia Vera market uptake by drugs, patient uptake by therapies, and sales of each drug.

SLN124: Silence Therapeutics
Bomedemstat (IMG-7289): Imago BioSciences
Rusfertide (PTG-300): Protagonist Therapeutics
BESREMi (ropeginterferon alfa-2b): PharmaEssentia/AOP Orphan Pharmaceuticals
JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis
And Others

Request for a sample report to understand more about the Polycythemia Vera pipeline development activities at: https://www.delveinsight.com/sample-request/polycythemia-vera-market

Polycythemia Vera Therapeutics Assessment

Major key companies are working proactively in the Polycythemia Vera Therapeutics market to develop novel therapies which will drive the Polycythemia Vera treatment markets in the upcoming years are Protagonist Therapeutics, Imago BioSciences, Italfarmaco, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics and others.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/sample-request/polycythemia-vera-market

Polycythemia Vera Report Key Insights

1. Polycythemia Vera Patient Population

2. Polycythemia Vera Market Size and Trends

3. Key Cross Competition in the Polycythemia Vera Market

4. Polycythemia Vera Market Dynamics (Key Drivers and Barriers)

5. Polycythemia Vera Market Opportunities

6. Polycythemia Vera Therapeutic Approaches

7. Polycythemia Vera Pipeline Analysis

8. Polycythemia Vera Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Polycythemia Vera Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Polycythemia Vera Competitive Intelligence Analysis

4. Polycythemia Vera Market Overview at a Glance

5. Polycythemia Vera Disease Background and Overview

6. Polycythemia Vera Patient Journey

7. Polycythemia Vera Epidemiology and Patient Population

8. Polycythemia Vera Treatment Algorithm, Current Treatment, and Medical Practices

9. Polycythemia Vera Unmet Needs

10. Key Endpoints of Polycythemia Vera Treatment

11. Polycythemia Vera Marketed Products

12. Polycythemia Vera Emerging Therapies

13. Polycythemia Vera Seven Major Market Analysis

14. Attribute Analysis

15. Polycythemia Vera Market Outlook (7 major markets)

16. Polycythemia Vera Access and Reimbursement Overview

17. KOL Views on the Polycythemia Vera Market

18. Polycythemia Vera Market Drivers

19. Polycythemia Vera Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Get the Detailed TOC of the Polycythemia Vera Market report here: https://www.delveinsight.com/sample-request/polycythemia-vera-market

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Treatment Market 2032: Epidemiology Analysis, Treatment, Therapies and Competitive Analysis by DelveInsight

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market

Anaplastic Lymphoma Kinase (ALK) rearrangements lead to the expression of constitutively activated ALK fusion proteins that function as potent oncogenic drivers. Since the discovery of ALK rearrangements in NSCLC, several ALK inhibitors have been developed for the treatment of patients with advanced ALK-rearranged NSCLC.

DelveInsight's "Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC), historical and forecasted epidemiology as well as the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a Free Sample Report @ https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market

Some facts of Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) market report:

The incident cases for ALK-positive mutation in the United States in 2019 were 8,449
The United States accounts for around 38% of the total patient population of ALK-Positive NSCLC among 7MM
In the case of EU-5, Germany hold up to around 29% of the EU-5 Patient population
Some of the factors driving the ALK-NSCLC market are Increasing Use of Biomarker Testing , Increase in the Mutation Specific Trials Activity and Approval, Increasing Incidence of NSCLC, Label expansion of approved therapies.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology

The Anaplastic lymphoma kinase Non-Small Cell Lung Cancer epidemiology section provides insights into the historical and current Anaplastic lymphoma kinase Non-Small Cell Lung Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the ALK-NSCLC market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Chronic Venous Insufficiency Epidemiology at: https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market

Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Epidemiological Segmentation

The Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiological Segmentation of Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) in 7MM from 2019 to 2032 is segmented as:-

Total Incidence of NSCLC
Total Incident cases of NSCLC patients by Histology
Total Diagnosed cases of NSCLC patients by Stages
Total ALK-NSCLC cases
ALK-NSCLC Treated Patient Pool

Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Market Drivers

Increasing Use of Biomarker Testing
Increase in the Mutation Specific Trials Activity and Approval
Increasing Incidence of NSCLC
Label expansion of approved therapies

Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Market Barriers

Cost-Effectiveness of Therapies
Small Patient Populations for Specific Subsets of NSCLC
Generic or Biosimilar Erosion

Learn more about Chronic Venous Insufficiency, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market

Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Emerging Drugs

The Emerging drugs of the Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) market are X-396 (Ensartinib), and many others.

Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Marketed Drugs

The Marketed drugs of the Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) market are Lorbrena/Lorviqua (Lorlatinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Xalkori, Zykadia and many others.

Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Companies

The key players in the Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) market are

Xcovery
Pfizer
Takeda Pharmaceuticals
Hoffmann-La Roche
Novartis
And many others.

Request for a free sample report here @ https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Key Insights

1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Patient Population

2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Size and Trends

3. Key Cross Competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market

4. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Dynamics (Key Drivers and Barriers)

5. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Opportunities

6. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Therapeutic Approaches

7. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Analysis

8. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Competitive Intelligence Analysis

4. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Overview at a Glance

5. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Disease Background and Overview

6. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Patient Journey

7. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Unmet Needs

10. Key Endpoints of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Treatment

11. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Marketed Products

12. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Emerging Therapies

13. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Outlook (7 major markets)

16. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Access and Reimbursement Overview

17. KOL Views on the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market

18. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Drivers

19. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Get the Detailed TOC of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market report here@ https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market

About DelveInsight

Burkitt Lymphoma Market Research Report 2032: Epidemiology Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

Burkitt Lymphoma Market

DelveInsight's Burkitt lymphoma Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Burkitt lymphoma, historical and forecasted epidemiology as well as the Burkitt lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Burkitt lymphoma is a form of non-Hodgkin's lymphomas (NHLs) which are a group of blood cancers derived from lymphocytes. Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin's lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated.

To know more about the Burkitt lymphoma market report offerings, click here: Burkitt Lymphoma Market Forecast

Some facts of Burkitt lymphoma Market are:

According to WebMD, in the United States, around 1,200 new cases are diagnosed each year.
Burkitt Lymphoma Society, the condition accounts for around 40% of the childhood non-Hodgkin lymphoma cases globally.
It also accounts for as many as 40% of all non-Hodgkin lymphomas in HIV/AIDS patients.
Burkitt lymphoma (BL) may be defined as an aggressive rare disorder that constitutes approximately 1% to 2% of all non-Hodgkin lymphomas.
Burkitt lymphoma is known as one of the most aggressive forms of lymphoma, with a doubling time of approximately 24 hours.
According to the Cancer Research UK, 2015, around 200,000 new cases and over 140,000 deaths are estimated to be recorded each year due to EBV-associated cancers.
According to the survey conducted by WebMD, LLC, in 2015, around 1,200 people are diagnosed each year in the U.S., of which around 59% are aged 40 years and above.
According to the survey by Lymphoma Action Organization, 2015, around 210 people are affected by Burkitt lymphoma every year in the U.K.

Request for Sample Report for Burkitt lymphoma market trends and epidemiology data: https://www.delveinsight.com/sample-request/burkitt-lymphoma-market

Scope of the Burkitt lymphoma Market Report

The report covers the descriptive overview of Burkitt lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Burkitt lymphoma epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Burkitt lymphoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Burkitt lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Burkitt lymphoma market

Request for Sample Report: https://www.delveinsight.com/sample-request/burkitt-lymphoma-market

Some Burkitt lymphoma Companies are:

Takeda Pharmaceutical
Novartis AG
Seattle Genetics, Inc
Sanofi
Mayo Clinic
MethylGene Inc
Eisai Inc
Cellerant Therapeutics
And Many Others

Some Burkitt lymphoma Therapies are:

RITUXIMAB
SGN-CD19A
Alisertib
Clofarabine
And Many Others

Request for Sample Report: https://www.delveinsight.com/sample-request/burkitt-lymphoma-market

Table of Contents:

1. Key Insights

2. Executive Summary of Burkitt lymphoma

3. Competitive Intelligence Analysis for Burkitt lymphoma

4. Burkitt lymphoma: Market Overview at a Glance

5. Burkitt lymphoma: Disease Background and Overview

5.1. Introduction

5.2. Burkitt lymphoma Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Burkitt lymphoma Diagnosis

6. Burkitt lymphoma Patient Journey

7. Burkitt lymphoma Epidemiology and Patient Population

8. Burkitt lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Burkitt lymphoma Treatment and Management

8.2. Burkitt lymphoma Treatment Algorithm

9. Burkitt lymphoma Unmet Needs

10. Key Endpoints of Burkitt lymphoma Treatment

11. Burkitt lymphoma Marketed Products

12. Emerging Burkitt lymphoma Therapies

13. Burkitt lymphoma: Seven Major Market Analysis

13.1. Key Findings

13.2. Burkitt lymphoma Market Size in 7MM

13.3. Burkitt lymphoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Burkitt lymphoma Market Outlook

16. Access and Reimbursement Overview of Burkitt lymphoma

17. KOL Views

18. Burkitt lymphoma Market Drivers

19. Burkitt lymphoma Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.